Eisai R&d Management Co., Ltd.

Eisai Company, Limited

Mercian Corporation

Naoki Asai

Yoshihiko Kotake

Jun Niijima

Takashi Sakai

Kiyoshi Okamoto

Mitsuo Nagai

Takashi Nakashima

Satoshi Yamamoto

Toshio Tsuchida

Masashi Yoshida

Kazuyuki Dobashi

Yoshiharu Mizui

Toshimitsu Uenaka

Tomohiro Sameshima

Naoto Kawamura

Takao Yamori

Masanori Fujita

Susumu Takeda

Regina Mikie Kanada

Motoko Matsufuji

Tomonari Yamada

Akifumi Okuda

Daisuke Ito

Keisuke Komeda

Kumiko Kishi

Masao Iwata

Koji Norihisa

Hachiro Sugimoto

Naoki Asakawa

Masahiro Yonaga

Taro Terauchi

Takashi Doko

Nariyasu Mano

Yukio Nishizawa

Akinori Akaike

Process for producing compound of Formula: wherein P, Pand Rare the same as defined below, characterized by comprising reacting a compound represented by Formula (7): wherein Pmeans a protecting group for hydroxy group; and Het means a 1-phenyl-1H-tetrazol-5-yl group, with a compound represented by Formula (8): wherein Pmeans a protecting group for hydroxy group; and Rmeans a phenyl group which may be substituted, in the presence of a base.

Process for total synthesis of pladienolide B and pladienolide D

A process for producing a compound represented by Formula (11): wherein P, P, P, Pand Rare the same as defined herein, characterized by including reacting a compound represented by Formula (12): with a compound represented by Formula (13): in the presence of a catalyst.

The present invention provides a novel bioactive substance having an antitumor activity and a process for producing it, and a medical use thereof. Namely, it provides a 12-membered ring macrolide compound represented by the following formula obtained from the incubation solution ofsp. Mer. 11107 or a variant thereof, a pharmacologically acceptable salt thereof or a hydrate of them, and a process for producing it. 

Bioactive substance

The present invention provides a novel compound exhibiting an excellent suppressing effect to cell injury caused by radicals and neurotoxicity induced by excitatory nuerotransmitters such as glutamate. Specifically, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. Wherein Z represents a bivalent organic group and the like of from 2 to 3 carbon atom(s) which may have a substituent; and Rrepresents a carboxyl group and the like.

Atisane compounds and use thereof

The present invention provides a novel bioactive substance having an antitumor activity and a process for producing it, and a medical use thereof. Namely, it provides a 12-membered ring macrolide compound represented by the following formula obtained from the incubation solution ofsp. Mer. 11107 or a variant thereof, a pharmacologically acceptable salt thereof or a hydrate of them, and a process for producing it

Physiologically active substances

Growing community of inventors

Ibaraki, Japan

Naoki Asai